Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: a multicenter study of 1521 patients
Methotrexate (MTX) is commonly used as first-line systemic treatment agent in psoriasis. We aimed to evaluate the clinical characteristics and treatment responses of patients with psoriasis undergoing MTX monotherapy. Data from adult patients with plaque psoriasis who received MTX monotherapy for at...
Saved in:
Published in | Archives of dermatological research Vol. 316; no. 6; p. 278 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin/Heidelberg
Springer Berlin Heidelberg
25.05.2024
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Methotrexate (MTX) is commonly used as first-line systemic treatment agent in psoriasis. We aimed to evaluate the clinical characteristics and treatment responses of patients with psoriasis undergoing MTX monotherapy. Data from adult patients with plaque psoriasis who received MTX monotherapy for at least 3 months between April 2012 and April 2022 were retrospectively evaluated in 19 tertiary care centers. Our study included 722 female and 799 male patients, a total of 1521 participants. The average age of the patients was 44.3 ± 15.5 years. Mode of treatment was oral in 20.4% of patients while in 79.4% it was subcutaneous. The median treatment duration was 8 months (
IQR
= 5–15). The median weekly dose was 15 mg (
IQR
= 11–15). 1448 (95.2%) patients were taking folic acid supplementation. At week 12, 16.3% of the patients achieved PASI (Psoriasis Area and Severity Index) 90 response while at week 24, 37.3% achieved it. Logistic regression analysis for week 12 identified the following independent factors affecting PASI 90 achievement positively: median weekly MTX dose ≤ 15 mg (
P
= 0.011), subcutaneous administration (
P
= 0.005), no prior systemic treatment (< 0.001) and folic acid use (0.021). In logistic regression analysis for week 24; median weekly MTX dose ≤ 15 mg (
P
= 0.001), baseline PASI ≥ 10 (
P
< 0.001), no prior systemic treatment (
P
< 0.004), folic acid use (
P
= 0.001) and absence of comorbidities (
P
= 0.009) were determined as independent factors affecting the achievement of PASI 90. Adverse effects were observed in 38.8% of the patients, with nausea/vomiting (23.9%) and transaminase elevation (13%) being the most common. The most common reasons for interruptions (15.3%) and discontinuations (27.1%) of the treatment were patient related individual factors. The use of MTX as the first systemic treatment agent, at doses ≤ 15 mg/week and concurrent folic acid application are positive predictive factors for achieving the target PASI response both at weeks 12 and 24. In our study, which is one of the most comprehensive studies on MTX treatment in psoriasis, we observed that MTX is an effective and safe treatment option. |
---|---|
AbstractList | Methotrexate (MTX) is commonly used as first-line systemic treatment agent in psoriasis. We aimed to evaluate the clinical characteristics and treatment responses of patients with psoriasis undergoing MTX monotherapy. Data from adult patients with plaque psoriasis who received MTX monotherapy for at least 3 months between April 2012 and April 2022 were retrospectively evaluated in 19 tertiary care centers. Our study included 722 female and 799 male patients, a total of 1521 participants. The average age of the patients was 44.3 ± 15.5 years. Mode of treatment was oral in 20.4% of patients while in 79.4% it was subcutaneous. The median treatment duration was 8 months (IQR = 5–15). The median weekly dose was 15 mg (IQR = 11–15). 1448 (95.2%) patients were taking folic acid supplementation. At week 12, 16.3% of the patients achieved PASI (Psoriasis Area and Severity Index) 90 response while at week 24, 37.3% achieved it. Logistic regression analysis for week 12 identified the following independent factors affecting PASI 90 achievement positively: median weekly MTX dose ≤ 15 mg (P = 0.011), subcutaneous administration (P = 0.005), no prior systemic treatment (< 0.001) and folic acid use (0.021). In logistic regression analysis for week 24; median weekly MTX dose ≤ 15 mg (P = 0.001), baseline PASI ≥ 10 (P < 0.001), no prior systemic treatment (P < 0.004), folic acid use (P = 0.001) and absence of comorbidities (P = 0.009) were determined as independent factors affecting the achievement of PASI 90. Adverse effects were observed in 38.8% of the patients, with nausea/vomiting (23.9%) and transaminase elevation (13%) being the most common. The most common reasons for interruptions (15.3%) and discontinuations (27.1%) of the treatment were patient related individual factors. The use of MTX as the first systemic treatment agent, at doses ≤ 15 mg/week and concurrent folic acid application are positive predictive factors for achieving the target PASI response both at weeks 12 and 24. In our study, which is one of the most comprehensive studies on MTX treatment in psoriasis, we observed that MTX is an effective and safe treatment option. Methotrexate (MTX) is commonly used as first-line systemic treatment agent in psoriasis. We aimed to evaluate the clinical characteristics and treatment responses of patients with psoriasis undergoing MTX monotherapy. Data from adult patients with plaque psoriasis who received MTX monotherapy for at least 3 months between April 2012 and April 2022 were retrospectively evaluated in 19 tertiary care centers. Our study included 722 female and 799 male patients, a total of 1521 participants. The average age of the patients was 44.3 ± 15.5 years. Mode of treatment was oral in 20.4% of patients while in 79.4% it was subcutaneous. The median treatment duration was 8 months (IQR = 5-15). The median weekly dose was 15 mg (IQR = 11-15). 1448 (95.2%) patients were taking folic acid supplementation. At week 12, 16.3% of the patients achieved PASI (Psoriasis Area and Severity Index) 90 response while at week 24, 37.3% achieved it. Logistic regression analysis for week 12 identified the following independent factors affecting PASI 90 achievement positively: median weekly MTX dose ≤ 15 mg (P = 0.011), subcutaneous administration (P = 0.005), no prior systemic treatment (< 0.001) and folic acid use (0.021). In logistic regression analysis for week 24; median weekly MTX dose ≤ 15 mg (P = 0.001), baseline PASI ≥ 10 (P < 0.001), no prior systemic treatment (P < 0.004), folic acid use (P = 0.001) and absence of comorbidities (P = 0.009) were determined as independent factors affecting the achievement of PASI 90. Adverse effects were observed in 38.8% of the patients, with nausea/vomiting (23.9%) and transaminase elevation (13%) being the most common. The most common reasons for interruptions (15.3%) and discontinuations (27.1%) of the treatment were patient related individual factors. The use of MTX as the first systemic treatment agent, at doses ≤ 15 mg/week and concurrent folic acid application are positive predictive factors for achieving the target PASI response both at weeks 12 and 24. In our study, which is one of the most comprehensive studies on MTX treatment in psoriasis, we observed that MTX is an effective and safe treatment option.Methotrexate (MTX) is commonly used as first-line systemic treatment agent in psoriasis. We aimed to evaluate the clinical characteristics and treatment responses of patients with psoriasis undergoing MTX monotherapy. Data from adult patients with plaque psoriasis who received MTX monotherapy for at least 3 months between April 2012 and April 2022 were retrospectively evaluated in 19 tertiary care centers. Our study included 722 female and 799 male patients, a total of 1521 participants. The average age of the patients was 44.3 ± 15.5 years. Mode of treatment was oral in 20.4% of patients while in 79.4% it was subcutaneous. The median treatment duration was 8 months (IQR = 5-15). The median weekly dose was 15 mg (IQR = 11-15). 1448 (95.2%) patients were taking folic acid supplementation. At week 12, 16.3% of the patients achieved PASI (Psoriasis Area and Severity Index) 90 response while at week 24, 37.3% achieved it. Logistic regression analysis for week 12 identified the following independent factors affecting PASI 90 achievement positively: median weekly MTX dose ≤ 15 mg (P = 0.011), subcutaneous administration (P = 0.005), no prior systemic treatment (< 0.001) and folic acid use (0.021). In logistic regression analysis for week 24; median weekly MTX dose ≤ 15 mg (P = 0.001), baseline PASI ≥ 10 (P < 0.001), no prior systemic treatment (P < 0.004), folic acid use (P = 0.001) and absence of comorbidities (P = 0.009) were determined as independent factors affecting the achievement of PASI 90. Adverse effects were observed in 38.8% of the patients, with nausea/vomiting (23.9%) and transaminase elevation (13%) being the most common. The most common reasons for interruptions (15.3%) and discontinuations (27.1%) of the treatment were patient related individual factors. The use of MTX as the first systemic treatment agent, at doses ≤ 15 mg/week and concurrent folic acid application are positive predictive factors for achieving the target PASI response both at weeks 12 and 24. In our study, which is one of the most comprehensive studies on MTX treatment in psoriasis, we observed that MTX is an effective and safe treatment option. Methotrexate (MTX) is commonly used as first-line systemic treatment agent in psoriasis. We aimed to evaluate the clinical characteristics and treatment responses of patients with psoriasis undergoing MTX monotherapy. Data from adult patients with plaque psoriasis who received MTX monotherapy for at least 3 months between April 2012 and April 2022 were retrospectively evaluated in 19 tertiary care centers. Our study included 722 female and 799 male patients, a total of 1521 participants. The average age of the patients was 44.3 ± 15.5 years. Mode of treatment was oral in 20.4% of patients while in 79.4% it was subcutaneous. The median treatment duration was 8 months ( IQR = 5–15). The median weekly dose was 15 mg ( IQR = 11–15). 1448 (95.2%) patients were taking folic acid supplementation. At week 12, 16.3% of the patients achieved PASI (Psoriasis Area and Severity Index) 90 response while at week 24, 37.3% achieved it. Logistic regression analysis for week 12 identified the following independent factors affecting PASI 90 achievement positively: median weekly MTX dose ≤ 15 mg ( P = 0.011), subcutaneous administration ( P = 0.005), no prior systemic treatment (< 0.001) and folic acid use (0.021). In logistic regression analysis for week 24; median weekly MTX dose ≤ 15 mg ( P = 0.001), baseline PASI ≥ 10 ( P < 0.001), no prior systemic treatment ( P < 0.004), folic acid use ( P = 0.001) and absence of comorbidities ( P = 0.009) were determined as independent factors affecting the achievement of PASI 90. Adverse effects were observed in 38.8% of the patients, with nausea/vomiting (23.9%) and transaminase elevation (13%) being the most common. The most common reasons for interruptions (15.3%) and discontinuations (27.1%) of the treatment were patient related individual factors. The use of MTX as the first systemic treatment agent, at doses ≤ 15 mg/week and concurrent folic acid application are positive predictive factors for achieving the target PASI response both at weeks 12 and 24. In our study, which is one of the most comprehensive studies on MTX treatment in psoriasis, we observed that MTX is an effective and safe treatment option. Methotrexate (MTX) is commonly used as first-line systemic treatment agent in psoriasis. We aimed to evaluate the clinical characteristics and treatment responses of patients with psoriasis undergoing MTX monotherapy. Data from adult patients with plaque psoriasis who received MTX monotherapy for at least 3 months between April 2012 and April 2022 were retrospectively evaluated in 19 tertiary care centers. Our study included 722 female and 799 male patients, a total of 1521 participants. The average age of the patients was 44.3 ± 15.5 years. Mode of treatment was oral in 20.4% of patients while in 79.4% it was subcutaneous. The median treatment duration was 8 months (IQR = 5-15). The median weekly dose was 15 mg (IQR = 11-15). 1448 (95.2%) patients were taking folic acid supplementation. At week 12, 16.3% of the patients achieved PASI (Psoriasis Area and Severity Index) 90 response while at week 24, 37.3% achieved it. Logistic regression analysis for week 12 identified the following independent factors affecting PASI 90 achievement positively: median weekly MTX dose ≤ 15 mg (P = 0.011), subcutaneous administration (P = 0.005), no prior systemic treatment (< 0.001) and folic acid use (0.021). In logistic regression analysis for week 24; median weekly MTX dose ≤ 15 mg (P = 0.001), baseline PASI ≥ 10 (P < 0.001), no prior systemic treatment (P < 0.004), folic acid use (P = 0.001) and absence of comorbidities (P = 0.009) were determined as independent factors affecting the achievement of PASI 90. Adverse effects were observed in 38.8% of the patients, with nausea/vomiting (23.9%) and transaminase elevation (13%) being the most common. The most common reasons for interruptions (15.3%) and discontinuations (27.1%) of the treatment were patient related individual factors. The use of MTX as the first systemic treatment agent, at doses ≤ 15 mg/week and concurrent folic acid application are positive predictive factors for achieving the target PASI response both at weeks 12 and 24. In our study, which is one of the most comprehensive studies on MTX treatment in psoriasis, we observed that MTX is an effective and safe treatment option. |
ArticleNumber | 278 |
Author | Öztürk, Perihan Yıldız, Sibel Gharehdaghi, Sheyda Akbaş, Ayşe Kartal, Selda Pelin Ermertcan, Aylin Türel Hayran, Yıldız Özer, İlkay Dikicier, Bahar Sevimli Topkarcı, Zeynep Erdemir, Vefa Aslı Demirseren, Deniz Botsalı, Bengü Reyhan Zorlu, Özge Emre, Selma Aytekin, Sema Solak, Eda Öksüm Işık, Lütfi Polat, Asude Kara Balcı, Didem Didar Doğan, Sinan Üstüner, Pelin Öztürkcan, Serap Kılıç, Arzu Daye, Munise Ataseven, Arzu Selçuk, Leyla Baykal Kalkan, Göknur Adışen, Esra Hızlı, Pelin Erduran, Funda Aksu, Esra Koku Borlu, Murat Albayrak, Hülya Gönülal, Melis Polat, Mualla Yaldız, Mahizer |
Author_xml | – sequence: 1 givenname: Funda surname: Erduran fullname: Erduran, Funda email: fnderdrn@gmail.com organization: Department of Dermatology TR, Ankara Bilkent City Hospital – sequence: 2 givenname: Selma surname: Emre fullname: Emre, Selma organization: Department of Dermatology TR, Ankara Yıldırım Beyazıt University – sequence: 3 givenname: Yıldız surname: Hayran fullname: Hayran, Yıldız organization: Department of Dermatology TR, Ankara Bilkent City Hospital – sequence: 4 givenname: Esra surname: Adışen fullname: Adışen, Esra organization: Faculty of Medicine, Department of Dermatology TR, Gazi University – sequence: 5 givenname: Asude Kara surname: Polat fullname: Polat, Asude Kara organization: Department of Dermatology TR, İstanbul Training and Research Hospital – sequence: 6 givenname: Pelin surname: Üstüner fullname: Üstüner, Pelin organization: Department of Dermatology TR, Nişantaşı University – sequence: 7 givenname: Serap surname: Öztürkcan fullname: Öztürkcan, Serap organization: Department of Dermatology TR, Manisa Celal Bayar University – sequence: 8 givenname: Perihan surname: Öztürk fullname: Öztürk, Perihan organization: Department of Dermatology TR, Kahramanmaraş Sütçü İmam University – sequence: 9 givenname: Aylin Türel surname: Ermertcan fullname: Ermertcan, Aylin Türel organization: Department of Dermatology TR, Manisa Celal Bayar University – sequence: 10 givenname: Leyla Baykal surname: Selçuk fullname: Selçuk, Leyla Baykal organization: Department of Dermatology TR, Karadeniz Technical University – sequence: 11 givenname: Esra Koku surname: Aksu fullname: Aksu, Esra Koku organization: Department of Dermatology TR, İstanbul Training and Research Hospital – sequence: 12 givenname: Ayşe surname: Akbaş fullname: Akbaş, Ayşe organization: Department of Dermatology TR, Ankara Bilkent City Hospital – sequence: 13 givenname: Göknur surname: Kalkan fullname: Kalkan, Göknur organization: Department of Dermatology TR, Ankara Yıldırım Beyazıt University – sequence: 14 givenname: Deniz surname: Demirseren fullname: Demirseren, Deniz organization: Department of Dermatology TR, Ankara Bilkent City Hospital – sequence: 15 givenname: Selda Pelin surname: Kartal fullname: Kartal, Selda Pelin organization: Department of Dermatology TR, Etlik City Hospital – sequence: 16 givenname: Zeynep surname: Topkarcı fullname: Topkarcı, Zeynep organization: Department of Dermatology TR, İstanbul Bakırköy Dr. Sadi Konuk Training and Reseach Hospital – sequence: 17 givenname: Arzu surname: Kılıç fullname: Kılıç, Arzu organization: Department of Dermatology TR, Balıkesir University – sequence: 18 givenname: Mahizer surname: Yaldız fullname: Yaldız, Mahizer organization: Department of Dermatology TR, Sakarya Training and Research Hospital – sequence: 19 givenname: Sema surname: Aytekin fullname: Aytekin, Sema organization: Department of Dermatology TR, Tekirdağ Namık Kemal University – sequence: 20 givenname: Pelin surname: Hızlı fullname: Hızlı, Pelin organization: Department of Dermatology TR, Balıkesir University – sequence: 21 givenname: Sheyda surname: Gharehdaghi fullname: Gharehdaghi, Sheyda organization: Faculty of Medicine, Department of Dermatology TR, Gazi University – sequence: 22 givenname: Murat surname: Borlu fullname: Borlu, Murat organization: Department of Dermatology TR, Kayseri Erciyes University – sequence: 23 givenname: Lütfi surname: Işık fullname: Işık, Lütfi organization: Department of Dermatology TR, Etlik City Hospital – sequence: 24 givenname: Bengü Reyhan surname: Botsalı fullname: Botsalı, Bengü Reyhan organization: Department of Dermatology TR, Etlik City Hospital – sequence: 25 givenname: Eda Öksüm surname: Solak fullname: Solak, Eda Öksüm organization: Department of Dermatology TR, Kayseri Erciyes University – sequence: 26 givenname: Hülya surname: Albayrak fullname: Albayrak, Hülya organization: Department of Dermatology TR, Tekirdağ Namık Kemal University – sequence: 27 givenname: Melis surname: Gönülal fullname: Gönülal, Melis organization: Department of Dermatology TR, İzmir City Hospital – sequence: 28 givenname: Didem Didar surname: Balcı fullname: Balcı, Didem Didar organization: Department of Dermatology TR, İzmir City Hospital – sequence: 29 givenname: Mualla surname: Polat fullname: Polat, Mualla organization: Department of Dermatology TR, Abant İzzet Baysal University – sequence: 30 givenname: Munise surname: Daye fullname: Daye, Munise organization: Department of Dermatology TR, Necmettin Erbakan University – sequence: 31 givenname: Arzu surname: Ataseven fullname: Ataseven, Arzu organization: Department of Dermatology TR, Necmettin Erbakan University – sequence: 32 givenname: Sibel surname: Yıldız fullname: Yıldız, Sibel organization: Department of Dermatology TR, Necmettin Erbakan University – sequence: 33 givenname: İlkay surname: Özer fullname: Özer, İlkay organization: Department of Dermatology TR, Necmettin Erbakan University – sequence: 34 givenname: Özge surname: Zorlu fullname: Zorlu, Özge organization: Department of Dermatology TR, Tekirdağ Namık Kemal University – sequence: 35 givenname: Sinan surname: Doğan fullname: Doğan, Sinan organization: Department of Dermatology TR, Bakırçay University, İzmir Çiğli Training and Research Hospital – sequence: 36 givenname: Vefa Aslı surname: Erdemir fullname: Erdemir, Vefa Aslı organization: Department of Dermatology TR, İstanbul Medeniyet University – sequence: 37 givenname: Bahar Sevimli surname: Dikicier fullname: Dikicier, Bahar Sevimli organization: Department of Dermatology TR, Sakarya Training and Research Hospital |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38796658$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kctq3TAQhkVJaC7tC3RRBN1043Zk2ZLd3SH0Egg0kBS6M7I8PlGwJVcjQ8-79GGrk5Ne6KIrDdL3_6OZ_4wd-eCRsRcC3ggA_ZYAKpAFlFUBEpQqxBN2KipZFqDar0d_1SfsjOgeskg34ik7kY1ulaqbU_Zj4820I0c8jHw0NoVI3PlxWtFb57c8mbjFxK83N5c8Ii3BExI3fuDkBuQ4jmjTg3rGdBdSxO8mIZ-DD-kOo1l22Y4vk_m2Il8oRGdyt3fc8HmdkrPoE0ZOaR12exNRl4IvJrl8T8_Y8WgmwueP5zn78uH97cWn4urzx8uLzVVhy1qlAk0t86jKaBxUXVqAxshGZavegBam7ZXuVa-hHqFSEkTTCtH22qrKWgkgz9nrg-8SQ_4mpW52ZHGajMewUpeXC7rSEmRGX_2D3oc15h3uKV1qXTaiyVR5oGwMRBHHboluNnHXCej22XWH7LqcXfeQXSey6OWj9drPOPyW_AorA_IAUH7yW4x_ev_H9ieIbqck |
Cites_doi | 10.1111/ijd.16652 10.1093/rheumatology/keab917 10.1001/archderm.1958.01560080060010 10.1111/j.1365-2133.2011.10615.x 10.1056/NEJMoa021359 10.1111/bjd.14816 10.1056/NEJMoa1010858 10.1111/j.1365-2133.1994.tb02901.x 10.1136/annrheumdis-2014-205228 10.1111/j.1365-2133.2011.10399.x 10.1007/s00415-004-0287-5 10.1111/ijd.15628 10.1111/dth.13051 10.1111/dth.13455 10.1016/j.ad.2010.04.002 10.1111/dth.15656 10.1093/rheumatology/keab304 10.3390/jcm8010015 10.1111/ced.15102 10.1080/09546634.2016.1273469 10.1111/ijd.12585 10.1111/j.1365-2133.2006.07289.x 10.1586/1744666X.2015.1026894 10.1001/jamadermatol.2022.0434 10.1517/14740338.2014.933805 10.1007/s13555-023-00930-2 10.1007/s40257-013-0017-9 10.1080/09546634.2022.2117539 10.1111/j.1365-2133.2008.08876.x |
ContentType | Journal Article |
Copyright | The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
Copyright_xml | – notice: The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 H94 K9. 7X8 |
DOI | 10.1007/s00403-024-03066-1 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Immunology Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1432-069X |
ExternalDocumentID | 10_1007_s00403_024_03066_1 38796658 |
Genre | Multicenter Study Journal Article |
GroupedDBID | --- -53 -5E -5G -BR -EM -~C .86 .VR 06C 06D 0R~ 0VY 199 1N0 203 23M 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2~H 30V 36B 406 408 409 40D 40E 5VS 67Z 6NX 78A 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAFGU AAHNG AAIAL AAJBT AAJKR AANZL AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN ABAKF ABBBX ABBXA ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABWNU ABXPI ACAOD ACBMV ACBRV ACBYP ACDTI ACGFS ACHSB ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACTTH ACVWB ACWMK ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEFQL AEFTE AEGAL AEGNC AEJHL AEJRE AEMSY AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFBBN AFLOW AFNRJ AFQWF AFWTZ AFZKB AGAYW AGDGC AGGBP AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AIMYW AITGF AJDOV AJRNO AJZVZ AKMHD AKQUC ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ AXYYD AZFZN B-. BA0 BGNMA CSCUP DDRTE DL5 DNIVK DPUIP EBLON EBS EIOEI ESBYG F5P FEDTE FERAY FFXSO FIGPU FNLPD FRRFC FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS HF~ HG5 HG6 HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX KDC KOV KPH LAS LLZTM M4Y MA- N9A NB0 NPVJJ NQJWS NU0 O93 O9G O9I O9J OAM P19 P2P P9S PF0 PT4 PT5 QOK QOR QOS R89 R9I RHV RIG ROL RPX RRX RSV S16 S1Z S27 S37 S3B SAP SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SZ9 SZN T13 TSG TSK TSV TT1 TUC U2A U9L UG4 UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z7V Z7W Z82 Z87 Z8O Z8P Z8Q Z8V Z91 ZMTXR ZOVNA ~EX ~KM CGR CUY CVF ECM EIF EMB NPM AAYXX CITATION 7T5 H94 K9. 7X8 |
ID | FETCH-LOGICAL-c256t-ea531436a7ed652c008a386152ba071a9b67b6b705f04630189119b7c64cc3003 |
IEDL.DBID | U2A |
ISSN | 1432-069X 0340-3696 |
IngestDate | Sat Aug 17 04:31:43 EDT 2024 Tue Sep 24 22:12:16 EDT 2024 Thu Sep 26 21:32:31 EDT 2024 Wed Oct 02 05:22:56 EDT 2024 Thu Jun 27 01:15:01 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | PASI 90 Side effects Psoriasis Methotrexate Subcutaneous |
Language | English |
License | 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c256t-ea531436a7ed652c008a386152ba071a9b67b6b705f04630189119b7c64cc3003 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 38796658 |
PQID | 3072772818 |
PQPubID | 47442 |
ParticipantIDs | proquest_miscellaneous_3060747303 proquest_journals_3072772818 crossref_primary_10_1007_s00403_024_03066_1 pubmed_primary_38796658 springer_journals_10_1007_s00403_024_03066_1 |
PublicationCentury | 2000 |
PublicationDate | 2024-05-25 |
PublicationDateYYYYMMDD | 2024-05-25 |
PublicationDate_xml | – month: 05 year: 2024 text: 2024-05-25 day: 25 |
PublicationDecade | 2020 |
PublicationPlace | Berlin/Heidelberg |
PublicationPlace_xml | – name: Berlin/Heidelberg – name: Germany – name: Heidelberg |
PublicationSubtitle | Founded in 1869 as Archiv für Dermatologie und Syphilis |
PublicationTitle | Archives of dermatological research |
PublicationTitleAbbrev | Arch Dermatol Res |
PublicationTitleAlternate | Arch Dermatol Res |
PublicationYear | 2024 |
Publisher | Springer Berlin Heidelberg Springer Nature B.V |
Publisher_xml | – name: Springer Berlin Heidelberg – name: Springer Nature B.V |
References | Attwa, Elkot, Abdelshafey, Hafez (CR4) 2019; 32 Ibrahim, Ahmed, Conway, Carey (CR28) 2018; 8 Yélamos, Puig (CR6) 2015; 11 Saurat, Langley, Reich, Unnebrink, Sasso, Kampman (CR8) 2011; 165 Flytström, Stenberg, Svensson, Bergbrant (CR11) 2008; 158 Damiani, Amerio, Bardazzi (CR3) 2023; 13 Prey, Paul (CR19) 2009; 160 Caldarola, De Luca, Mariani, Chiricozzi, Peris, De Simone (CR29) 2023; 62 Choonhakarn, Chaowattanapanit, Julanon, Limpawattana (CR14) 2022; 47 Carretero, Puig, Dehesa (CR5) 2010; 101 van Huizen, Sikkel, Caron, Menting, Spuls (CR12) 2022; 33 Warren, Weatherhead, Smith (CR13) 2016; 175 Lajevardi, Hallaji, Daklan, Abedini, Goodarzi, Abdolreza (CR22) 2015; 54 Ozkok Akbulut, Topaloglu Demir, Oguz Topal (CR30) 2021; 60 Cabello Zurita, Grau Pérez, Hernández Fernández (CR31) 2017; 28 Barker, Hoffmann, Wozel (CR9) 2011; 165 van Huizen AM, Menting SP, Gyulai R (CR16) 2022; 158 Salim, Tan, Ilchyshyn, Berth-Jones (CR17) 2006; 154 Renard, Westhovens, Vandenbussche, Vandenberghe (CR25) 2004; 251 Dogra, Singh, Kumar, Narang, Handa (CR15) 2022; 35 Heydendael, Spuls, Opmeer (CR10) 2003; 349 Golbari, Porter, Kimball (CR1) 2018; 101 Lajevardi, Kashiri, Ghiasi, Khosravi, Fazlolahi, Etesami (CR21) 2020; 33 Van Dooren-Greebe, Kuijpers, Mulder, De Boo, Van de Kerkhof (CR32) 1994; 130 Edmundson, Guy (CR2) 1958; 78 Reich, Langley, Papp (CR23) 2011; 365 Masuria, Mittal, Gupta, Sharma, Bansal (CR18) 1997; 63 Sherbini, Sharma, Gwinnutt, Hyrich, Verstappen (CR27) 2021; 60 Al-Dabagh, Davis, Kinney, Huang, Feldman (CR20) 2013; 14 Sherbini, Gwinnutt, Hyrich, Co-Investigators, Verstappen (CR26) 2022; 61 Baran, Batycka-Baran, Zychowska, Bieniek, Szepietowski (CR24) 2014; 13 Schiff, Jaffe, Freundlich (CR7) 2014; 73 RB Warren (3066_CR13) 2016; 175 AA Sherbini (3066_CR27) 2021; 60 J Barker (3066_CR9) 2011; 165 van Huizen AM, Menting SP, Gyulai (3066_CR16) 2022; 158 NM Golbari (3066_CR1) 2018; 101 T Ozkok Akbulut (3066_CR30) 2021; 60 O Yélamos (3066_CR6) 2015; 11 C Choonhakarn (3066_CR14) 2022; 47 A Salim (3066_CR17) 2006; 154 I Flytström (3066_CR11) 2008; 158 W Baran (3066_CR24) 2014; 13 WF Edmundson (3066_CR2) 1958; 78 K Reich (3066_CR23) 2011; 365 S Dogra (3066_CR15) 2022; 35 G Caldarola (3066_CR29) 2023; 62 C Cabello Zurita (3066_CR31) 2017; 28 RJ Van Dooren-Greebe (3066_CR32) 1994; 130 AA Sherbini (3066_CR26) 2022; 61 G Damiani (3066_CR3) 2023; 13 AM van Huizen (3066_CR12) 2022; 33 A Ibrahim (3066_CR28) 2018; 8 BL Masuria (3066_CR18) 1997; 63 V Lajevardi (3066_CR21) 2020; 33 V Lajevardi (3066_CR22) 2015; 54 JH Saurat (3066_CR8) 2011; 165 S Prey (3066_CR19) 2009; 160 G Carretero (3066_CR5) 2010; 101 EM Attwa (3066_CR4) 2019; 32 VM Heydendael (3066_CR10) 2003; 349 MH Schiff (3066_CR7) 2014; 73 A Al-Dabagh (3066_CR20) 2013; 14 D Renard (3066_CR25) 2004; 251 |
References_xml | – volume: 62 start-page: 649 issue: 5 year: 2023 end-page: 656 ident: CR29 article-title: Drug survival of methotrexate and predictor factors for discontinuation in psoriasis publication-title: Int J Dermatol doi: 10.1111/ijd.16652 contributor: fullname: De Simone – volume: 61 start-page: 3930 issue: 10 year: 2022 end-page: 3938 ident: CR26 article-title: Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study publication-title: Rheumatology doi: 10.1093/rheumatology/keab917 contributor: fullname: Verstappen – volume: 78 start-page: 200 year: 1958 end-page: 202 ident: CR2 article-title: Treatment of psoriasis with folic acid antagonists publication-title: AMA Arch Dermatol doi: 10.1001/archderm.1958.01560080060010 contributor: fullname: Guy – volume: 165 start-page: 1109 issue: 5 year: 2011 end-page: 1117 ident: CR9 article-title: Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1) publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2011.10615.x contributor: fullname: Wozel – volume: 349 start-page: 658 issue: 7 year: 2003 end-page: 665 ident: CR10 article-title: Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis publication-title: N Engl J Med doi: 10.1056/NEJMoa021359 contributor: fullname: Opmeer – volume: 175 start-page: 23 issue: 1 year: 2016 end-page: 44 ident: CR13 article-title: British association of dermatologists' guidelines for the safe and effective prescribing of methotrexate for skin disease 2016 publication-title: Br J Dermatol doi: 10.1111/bjd.14816 contributor: fullname: Smith – volume: 365 start-page: 1586 issue: 17 year: 2011 end-page: 1596 ident: CR23 article-title: A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis publication-title: N Engl J Med doi: 10.1056/NEJMoa1010858 contributor: fullname: Papp – volume: 130 start-page: 204 issue: 2 year: 1994 end-page: 210 ident: CR32 article-title: Methotrexate revisited: effects of long-term treatment in psoriasis publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.1994.tb02901.x contributor: fullname: Van de Kerkhof – volume: 73 start-page: 1549 issue: 8 year: 2014 end-page: 1551 ident: CR7 article-title: Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2014-205228 contributor: fullname: Freundlich – volume: 165 start-page: 399 issue: 2 year: 2011 end-page: 406 ident: CR8 article-title: Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2011.10399.x contributor: fullname: Kampman – volume: 251 start-page: 226 issue: 2 year: 2004 end-page: 228 ident: CR25 article-title: Reversible posterior leucoencephalopathy during oral treatment with methotrexate publication-title: J Neurol doi: 10.1007/s00415-004-0287-5 contributor: fullname: Vandenberghe – volume: 60 start-page: 1140 issue: 9 year: 2021 end-page: 1147 ident: CR30 article-title: Drug survival and predictor factors for discontinuation of methotrexate in psoriasis: a real-life multicenter study publication-title: Int J Dermatol doi: 10.1111/ijd.15628 contributor: fullname: Oguz Topal – volume: 63 start-page: 219 issue: 4 year: 1997 end-page: 222 ident: CR18 article-title: Methotrexate: side effects and the role of folic acid supplementation in psoriasis—a study publication-title: Indian J Dermatol Venereol Leprol contributor: fullname: Bansal – volume: 32 issue: 5 year: 2019 ident: CR4 article-title: Subcutaneous methotrexate versus oral form for the treatment and prophylaxis of chronic plaque psoriasis publication-title: Dermatol Ther doi: 10.1111/dth.13051 contributor: fullname: Hafez – volume: 158 start-page: 116 issue: 1 year: 2008 end-page: 121 ident: CR11 article-title: Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. a randomized controlled trial publication-title: Br J Dermatol contributor: fullname: Bergbrant – volume: 33 issue: 4 year: 2020 ident: CR21 article-title: Evaluating the efficacy of ursodeoxycholic acid plus methotrexate vs methotrexate alone in the treatment of moderate to severe plaque-type psoriasis: a randomized clinical trial publication-title: Dermatol Ther doi: 10.1111/dth.13455 contributor: fullname: Etesami – volume: 101 start-page: 600 issue: 7 year: 2010 end-page: 613 ident: CR5 article-title: Metotrexato: guía de uso en psoriasis [Guidelines on the use of methotrexate in psoriasis] publication-title: Actas Dermosifiliogr doi: 10.1016/j.ad.2010.04.002 contributor: fullname: Dehesa – volume: 35 issue: 8 year: 2022 ident: CR15 article-title: Comparison of overall efficacy and safety of oral versus subcutaneous methotrexate in severe psoriasis publication-title: Dermatol Ther doi: 10.1111/dth.15656 contributor: fullname: Handa – volume: 60 start-page: 4001 issue: 9 year: 2021 end-page: 4017 ident: CR27 article-title: Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review publication-title: Rheumatology doi: 10.1093/rheumatology/keab304 contributor: fullname: Verstappen – volume: 8 start-page: 15 issue: 1 year: 2018 ident: CR28 article-title: Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis publication-title: J Clin Med doi: 10.3390/jcm8010015 contributor: fullname: Carey – volume: 101 start-page: 10 issue: 3S year: 2018 end-page: 12 ident: CR1 article-title: Current guidelines for psoriasis treatment: a work in progress publication-title: Cutis contributor: fullname: Kimball – volume: 47 start-page: 942 issue: 5 year: 2022 end-page: 948 ident: CR14 article-title: Comparison of the clinical efficacy of subcutaneous vs oral administration of methotrexate in patients with psoriasis vulgaris: a randomized controlled trial publication-title: Clin Exp Dermatol doi: 10.1111/ced.15102 contributor: fullname: Limpawattana – volume: 28 start-page: 401 issue: 5 year: 2017 end-page: 405 ident: CR31 article-title: Effectiveness and safety of methotrexate in psoriasis: an eight-year experience with 218 patients publication-title: J Dermatolog Treat doi: 10.1080/09546634.2016.1273469 contributor: fullname: Hernández Fernández – volume: 54 start-page: 95 issue: 1 year: 2015 end-page: 101 ident: CR22 article-title: The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial publication-title: Int J Dermatol doi: 10.1111/ijd.12585 contributor: fullname: Abdolreza – volume: 154 start-page: 1169 issue: 6 year: 2006 end-page: 1174 ident: CR17 article-title: Folic acid supplementation during treatment of psoriasis with methotrexate: a randomized, double-blind, placebo-controlled trial publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2006.07289.x contributor: fullname: Berth-Jones – volume: 11 start-page: 553 issue: 5 year: 2015 end-page: 563 ident: CR6 article-title: Systemic methotrexate for the treatment of psoriasis publication-title: Expert Rev Clin Immunol doi: 10.1586/1744666X.2015.1026894 contributor: fullname: Puig – volume: 158 start-page: 561 issue: 5 year: 2022 end-page: 572 ident: CR16 article-title: International eDelphi study to reach consensus on the methotrexate dosing regimen in patients with psoriasis publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2022.0434 contributor: fullname: van Huizen AM, Menting SP, Gyulai R – volume: 13 start-page: 1015 issue: 8 year: 2014 end-page: 1021 ident: CR24 article-title: Folate supplementation reduces the side effects of methotrexate therapy for psoriasis publication-title: Expert Opin Drug Saf doi: 10.1517/14740338.2014.933805 contributor: fullname: Szepietowski – volume: 13 start-page: 1219 issue: 6 year: 2023 end-page: 1241 ident: CR3 article-title: Real-world experience of methotrexate in the treatment of skin diseases: an Italian Delphi consensus publication-title: Dermatol Ther doi: 10.1007/s13555-023-00930-2 contributor: fullname: Bardazzi – volume: 14 start-page: 155 issue: 3 year: 2013 end-page: 161 ident: CR20 article-title: The effect of folate supplementation on methotrexate efficacy and toxicity in psoriasis patients and folic acid use by dermatologists in the USA publication-title: Am J Clin Dermatol doi: 10.1007/s40257-013-0017-9 contributor: fullname: Feldman – volume: 33 start-page: 3104 issue: 8 year: 2022 end-page: 3118 ident: CR12 article-title: Methotrexate dosing regimen for plaque-type psoriasis: an update of a systematic review publication-title: J Dermatolog Treat doi: 10.1080/09546634.2022.2117539 contributor: fullname: Spuls – volume: 160 start-page: 622 issue: 3 year: 2009 end-page: 628 ident: CR19 article-title: Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: a systematic review publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2008.08876.x contributor: fullname: Paul – volume: 365 start-page: 1586 issue: 17 year: 2011 ident: 3066_CR23 publication-title: N Engl J Med doi: 10.1056/NEJMoa1010858 contributor: fullname: K Reich – volume: 62 start-page: 649 issue: 5 year: 2023 ident: 3066_CR29 publication-title: Int J Dermatol doi: 10.1111/ijd.16652 contributor: fullname: G Caldarola – volume: 35 issue: 8 year: 2022 ident: 3066_CR15 publication-title: Dermatol Ther doi: 10.1111/dth.15656 contributor: fullname: S Dogra – volume: 32 issue: 5 year: 2019 ident: 3066_CR4 publication-title: Dermatol Ther doi: 10.1111/dth.13051 contributor: fullname: EM Attwa – volume: 165 start-page: 399 issue: 2 year: 2011 ident: 3066_CR8 publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2011.10399.x contributor: fullname: JH Saurat – volume: 14 start-page: 155 issue: 3 year: 2013 ident: 3066_CR20 publication-title: Am J Clin Dermatol doi: 10.1007/s40257-013-0017-9 contributor: fullname: A Al-Dabagh – volume: 78 start-page: 200 year: 1958 ident: 3066_CR2 publication-title: AMA Arch Dermatol doi: 10.1001/archderm.1958.01560080060010 contributor: fullname: WF Edmundson – volume: 158 start-page: 561 issue: 5 year: 2022 ident: 3066_CR16 publication-title: JAMA Dermatol doi: 10.1001/jamadermatol.2022.0434 contributor: fullname: van Huizen AM, Menting SP, Gyulai – volume: 349 start-page: 658 issue: 7 year: 2003 ident: 3066_CR10 publication-title: N Engl J Med doi: 10.1056/NEJMoa021359 contributor: fullname: VM Heydendael – volume: 160 start-page: 622 issue: 3 year: 2009 ident: 3066_CR19 publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2008.08876.x contributor: fullname: S Prey – volume: 61 start-page: 3930 issue: 10 year: 2022 ident: 3066_CR26 publication-title: Rheumatology doi: 10.1093/rheumatology/keab917 contributor: fullname: AA Sherbini – volume: 13 start-page: 1219 issue: 6 year: 2023 ident: 3066_CR3 publication-title: Dermatol Ther doi: 10.1007/s13555-023-00930-2 contributor: fullname: G Damiani – volume: 28 start-page: 401 issue: 5 year: 2017 ident: 3066_CR31 publication-title: J Dermatolog Treat doi: 10.1080/09546634.2016.1273469 contributor: fullname: C Cabello Zurita – volume: 251 start-page: 226 issue: 2 year: 2004 ident: 3066_CR25 publication-title: J Neurol doi: 10.1007/s00415-004-0287-5 contributor: fullname: D Renard – volume: 101 start-page: 600 issue: 7 year: 2010 ident: 3066_CR5 publication-title: Actas Dermosifiliogr doi: 10.1016/j.ad.2010.04.002 contributor: fullname: G Carretero – volume: 8 start-page: 15 issue: 1 year: 2018 ident: 3066_CR28 publication-title: J Clin Med doi: 10.3390/jcm8010015 contributor: fullname: A Ibrahim – volume: 130 start-page: 204 issue: 2 year: 1994 ident: 3066_CR32 publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.1994.tb02901.x contributor: fullname: RJ Van Dooren-Greebe – volume: 165 start-page: 1109 issue: 5 year: 2011 ident: 3066_CR9 publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2011.10615.x contributor: fullname: J Barker – volume: 60 start-page: 1140 issue: 9 year: 2021 ident: 3066_CR30 publication-title: Int J Dermatol doi: 10.1111/ijd.15628 contributor: fullname: T Ozkok Akbulut – volume: 63 start-page: 219 issue: 4 year: 1997 ident: 3066_CR18 publication-title: Indian J Dermatol Venereol Leprol contributor: fullname: BL Masuria – volume: 11 start-page: 553 issue: 5 year: 2015 ident: 3066_CR6 publication-title: Expert Rev Clin Immunol doi: 10.1586/1744666X.2015.1026894 contributor: fullname: O Yélamos – volume: 13 start-page: 1015 issue: 8 year: 2014 ident: 3066_CR24 publication-title: Expert Opin Drug Saf doi: 10.1517/14740338.2014.933805 contributor: fullname: W Baran – volume: 33 start-page: 3104 issue: 8 year: 2022 ident: 3066_CR12 publication-title: J Dermatolog Treat doi: 10.1080/09546634.2022.2117539 contributor: fullname: AM van Huizen – volume: 154 start-page: 1169 issue: 6 year: 2006 ident: 3066_CR17 publication-title: Br J Dermatol doi: 10.1111/j.1365-2133.2006.07289.x contributor: fullname: A Salim – volume: 175 start-page: 23 issue: 1 year: 2016 ident: 3066_CR13 publication-title: Br J Dermatol doi: 10.1111/bjd.14816 contributor: fullname: RB Warren – volume: 73 start-page: 1549 issue: 8 year: 2014 ident: 3066_CR7 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2014-205228 contributor: fullname: MH Schiff – volume: 60 start-page: 4001 issue: 9 year: 2021 ident: 3066_CR27 publication-title: Rheumatology doi: 10.1093/rheumatology/keab304 contributor: fullname: AA Sherbini – volume: 47 start-page: 942 issue: 5 year: 2022 ident: 3066_CR14 publication-title: Clin Exp Dermatol doi: 10.1111/ced.15102 contributor: fullname: C Choonhakarn – volume: 101 start-page: 10 issue: 3S year: 2018 ident: 3066_CR1 publication-title: Cutis contributor: fullname: NM Golbari – volume: 158 start-page: 116 issue: 1 year: 2008 ident: 3066_CR11 publication-title: Br J Dermatol contributor: fullname: I Flytström – volume: 33 issue: 4 year: 2020 ident: 3066_CR21 publication-title: Dermatol Ther doi: 10.1111/dth.13455 contributor: fullname: V Lajevardi – volume: 54 start-page: 95 issue: 1 year: 2015 ident: 3066_CR22 publication-title: Int J Dermatol doi: 10.1111/ijd.12585 contributor: fullname: V Lajevardi |
SSID | ssj0007781 |
Score | 2.4239213 |
Snippet | Methotrexate (MTX) is commonly used as first-line systemic treatment agent in psoriasis. We aimed to evaluate the clinical characteristics and treatment... |
SourceID | proquest crossref pubmed springer |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 278 |
SubjectTerms | Acids Administration, Oral Adult Comorbidity Dermatologic Agents - administration & dosage Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use Dermatology Female Folic acid Folic Acid - administration & dosage Folic Acid - therapeutic use Humans Injections, Subcutaneous Male Medicine Medicine & Public Health Methotrexate Methotrexate - administration & dosage Methotrexate - adverse effects Methotrexate - therapeutic use Middle Aged Original Paper Patients Psoriasis Psoriasis - diagnosis Psoriasis - drug therapy Regression analysis Retrospective Studies Severity of Illness Index Transaminase Treatment Outcome Vitamin B |
Title | Analysis of factors influencing target PASI responses and side effects of methotrexate monotherapy in plaque psoriasis: a multicenter study of 1521 patients |
URI | https://link.springer.com/article/10.1007/s00403-024-03066-1 https://www.ncbi.nlm.nih.gov/pubmed/38796658 https://www.proquest.com/docview/3072772818/abstract/ https://www.proquest.com/docview/3060747303/abstract/ |
Volume | 316 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dS8MwEA-iIL6I384vTvBNA1vTpJ1vU5xfTAQdzKeStCkI0o1tgv4v_rHepWmHTB986kOTS-hd7n7pfTF2oppGC2lynoWp5GFMetCKjKOxybM4pnIv9L-j96Bu-uHdQA5medwu2L3ySDpFXee6kbiRyzHkBHMVxyvPEoEHEuV-0KnVbxTFLZ8d8_u8nxZoDlbOuUSdpemusVUPEaFT8nSdLdhigy33vBN8k31VhURgmIPvlwOvvtkIUoQyuhseO0-3MC5jYO0EdJEB9eYEH8JBs13_6OnYfiDiBBRIn471ieRg9KZxyzCaDFFGcbVz0ODCDyme047BFaYlImSbwddnnWyxfvfq-fKG-yYLPEW0M-VW4ykMhdKRzZQMUsQEWsSIcwKjEX7otlGRUSZqypyKizVbMarHtolSFaapQJ2wzRaLYWF3GQihRWaligIZhCKOTBi3dSaVTZtC5qLdYKfVh09GZS2NpK6a7NiUIJsSx6ak1WAHFW8Sf64mCWqkAO8DiDIa7Lh-jSeC3By6sMN3GqOoKwDa5gbbKXlaL4e7wvudxNlnFZNnxP_ey97_hu-zlcAJnOSBPGCL0_G7PUTsMjVHbKnTvbh4oOf1y_3VkZPdb9CY6QA |
link.rule.ids | 315,786,790,27957,27958,41116,41558,42185,42627,52146,52269 |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1JT9tAFH5CQYJeytKWhvUh9dYOSjyLHW4RgoYlqBJEoidrxh5LVSsnih2p8Fv4sbyxx64o7YGzPYvfvOUbvw3gk-oZzaXJWCoSyUTk9KDlKSNjk6VR5Mq9uP8d42s1moiLO3nnk8KKJtq9cUlWmrpNdnP85nyOgjmcqxjdeZYFWSjZgeXh1--Xp60GDsOo7xNk_j3yuRF6gSxfeEUrY3O2BpNmm3WMyc-jRWmOkoe_Kji-9jvW4a1Hnzis2WUDlmy-CStj719_B49NjRKcZuhb8eAP38eEFsE6cBy_DW_OcV6H19oCdZ6ia_uJPjrEja5aU5dz-5vALBKv-0yve5oOZ780kQJnxZTYn1Y7Ro1VZKMLFbVzrGreukmc2Udf-rV4D5Oz09uTEfP9G1hCQKpkVpOAC650aFMlg4TghuYRQajAaEI2emBUaJQJezJzdct6_Yg078CEiRJJwkndfIBOPs3tR0DONU-tVGEgA8Gj0IhooFOpbNLjMuODLnxuDjSe1WU64rYgc0XwmAgeVwSP-13Ybc489iJbxKTsArpqEIDpwmH7mITNeVB0bqcL945yDQfI7Hdhq-aVdjnaFV0dJY3-0pz7n8n_v5ft171-AKuj2_FVfHV-fbkDb4KKjSQL5C50yvnC7hFEKs2-l4gnXS8GPw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwEB5VICEuPMprKbSDxI0aduNHsr2tgAXKQ0iABKfIThwJgbKr3axU-lv6YztOnEBLOaCeEz9iz4w_Z2a-AdhWbaO5NBlLRSKZiJwdtDxldNhkaRQ5uhf3v-P8Qh3fiO-38vZFFn8Z7V67JKucBsfSlBd7wzTbaxLfnOw5_6NgDvMqRvefaUFqSzI-3Tu6Oz1srHEYRh2fLPPvln8eSK9Q5isPaXnw9OdB11Ou4k0edieF2U1-_sXm-D_ftABzHpVirxKjRfhg848wc-797kvwq-YuwUGGvkQP3vv6JjQgVgHleNm7OsFRFXZrx6jzFF05UPRRI651WbK6GNkfBHKRdMBngD1Rdzh81LQsOBwPSC1otG-osYx4dCGkdoQlF67rxMEB9JSw42W46R9e7x8zX9eBJQSwCmY1Kb7gSoc2VTJICIZoHhG0CowmxKO7RoVGmbAtM8dn1u5EZJG7JkyUSBJOZmgFpvJBbtcAOdc8tVKFgQwEj0Ijoq5OpbJJm8uMd1uwU29uPKzoO-KGqLlc8JgWPC4XPO60YKPe_9ir8jgmIxjQFYSATQu2msekhM6zonM7mLh3lCtEQHCgBauV3DTD0azoSimp9ddaBp47f3su6-97_QvMXB7047OTi9NPMBuUUiRZIDdgqhhN7CYhp8J89srxG3otDxo |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Analysis+of+factors+influencing+target+PASI+responses+and+side+effects+of+methotrexate+monotherapy+in+plaque+psoriasis%3A+a+multicenter+study+of+1521+patients&rft.jtitle=Archives+of+dermatological+research&rft.au=Erduran%2C+Funda&rft.au=Emre%2C+Selma&rft.au=Hayran%2C+Y%C4%B1ld%C4%B1z&rft.au=Ad%C4%B1%C5%9Fen%2C+Esra&rft.date=2024-05-25&rft.pub=Springer+Berlin+Heidelberg&rft.eissn=1432-069X&rft.volume=316&rft.issue=6&rft_id=info:doi/10.1007%2Fs00403-024-03066-1&rft.externalDocID=10_1007_s00403_024_03066_1 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1432-069X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1432-069X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1432-069X&client=summon |